SB 32 (2019): reestablishing the commission to study greater transparency in pharmaceutical costs and drug rebate programs.

Cite this page

Granite Record indexes the General Court’s record; it is not that record. Where a citation allows only one source, cite the General Court — every page here links to what it is drawn from. The date below is the day the page was read.

MLA
“SB 32 (2019): reestablishing the commission to study greater transparency in pharmaceutical costs and drug rebate programs.” Granite Record, https://graniterecord.org/bill/2019/sb32. Accessed 24 Oct. 2026.
APA
Granite Record. (n.d.). SB 32 (2019): reestablishing the commission to study greater transparency in pharmaceutical costs and drug rebate programs. Retrieved 24 Oct. 2026, from https://graniterecord.org/bill/2019/sb32
Chicago
Granite Record. “SB 32 (2019): reestablishing the commission to study greater transparency in pharmaceutical costs and drug rebate programs.” Accessed 24 Oct. 2026. https://graniterecord.org/bill/2019/sb32.
BibTeX
@misc{bill-2019-sb32, title = {SB 32 (2019): reestablishing the commission to study greater transparency in pharmaceutical costs and drug rebate programs.}, howpublished = {Granite Record}, url = {https://graniterecord.org/bill/2019/sb32}, note = {Accessed 24 Oct. 2026} }

SB 32 (2019)

reestablishing the commission to study greater transparency in pharmaceutical costs and drug rebate programs.

  • Status: Killed
  • Term: 2019-2020
  • Senate committee: Health and Human Services
  • Subject: Study Committees and Commissions

The Story

It was introduced on January 3, 2019 and referred to the Senate Health and Human Services committee. The committee held a public hearing on January 29, 2019. The committee voted unanimously, 5–0, to recommend that the Senate kill it, and the report was placed on the consent calendar. On March 21, 2019 the Senate voted to kill it on a voice vote.

Sponsors

Hearings and Sessions

  • January 29, 2019, 1:50 PM: hearing, Senate Health and Human Services, LOB 101

Votes

  • March 21, 2019, Senate: Inexpedient to Legislate — voice vote, passed

The Docket

  • January 3, 2019: Introduced 01/03/2019 and Referred to Health and Human Services
  • January 29, 2019: Hearing: 01/29/2019, Room 101, LOB, 01:50 pm
  • March 21, 2019: Committee Report: Inexpedient to Legislate; Vote 5-0; CC; 03/21/2019
  • March 21, 2019: Inexpedient to Legislate, MA, VV ; 03/21/2019

Laws It Would Change

Related Bills

  • SB 226-FN (2019): relative to registration of pharmacy benefit managers, and reestablishing the commission to study greater transparency in pharmaceutical costs and drug rebate programs.
  • SB 226-FN (2019): relative to registration of pharmacy benefit managers, and reestablishing the commission to study greater transparency in pharmaceutical costs and drug rebate programs.
  • SB 226-FN (2019): relative to registration of pharmacy benefit managers, and reestablishing the commission to study greater transparency in pharmaceutical costs and drug rebate programs.
  • HB 1418-FN (2018): relative establishing a commission to study greater transparency in pharmaceutical costs and drug rebate programs.
  • HB 1418-FN (2018): relative establishing a commission to study greater transparency in pharmaceutical costs and drug rebate programs.

From the General Court